Contrast Agents (Global Market)
Contrast agents (or agents) are drugs administered to a hollow organ, cavity in the body, or blood flow and provide contrast enhancement in radiological examination methods. Contrast agents are used to visualize the vascular bed, the internal relief of the digestive and excretory systems, the nature of accumulation and excretion of the contrast drug by parenchymal organs , etc.
Main article: Radiology (radiation diagnostics)
2023: Instead of poisonous gadolinium. Fresenius unveils MRI contrast agent substitute
On August 8, 2023, Fresenius Kabi announced the release of Gadobutrol, a universal contrast agent substitute for Gadavist, which is used in magnetic resonance imaging (MRI) procedures. Read more here.
2022: Fresenius releases new contrast agent amid global shortage
On July 18, 2022, Fresenius Kabi announced the release of new contrast media - Iodixanol Injection, USP. The statement was made against the background of an acute shortage of such drugs around the world. Read more here.
2020: Nanoparticles created that can be used for magnetic diagnosis and therapy of cancer
On September 7, 2020, it became known that scientists at NUST MISIS together with colleagues from the Institute of Organic Chemistry named after N.D. Zelinsky RAS and the Institute of Physical Chemistry and Electrochemistry named after A.N. Frumkin RAS created a hybrid structure of magnetic nanoparticles and humic molecules. The proposed hybrid is biocompatible, its production does not require high costs, and in the future it can be used for magnetic diagnostics and high-temperature therapy of cancer. An article on the development was published in Nanomaterials.
As explained, as of September 2020, one of the most effective ways to detect cancer at an early stage is magnetic resonance imaging (MRI). To improve accuracy, a special contrast magnetic agent can be introduced into the body to additionally "illuminate" malignant formations. The same agent can be used for subsequent therapy - under the influence of high temperatures, particles will heat up and destroy cancer cells. Read more here.
2016: MarketsandMarkets: Market size $4.5 billion
In October 2016, the analytical company MarketsandMarkets released a study of the global contrast agents market. Its volume, as experts predict, will increase by 22% in five years.
According to researchers' expectations, in 2016, the global costs of medical institutions for the purchase of contrast agents will amount to $4.46 billion, and by 2021 this figure will reach $5.44 billion. Thus, the estimated average annual growth rate of the market is estimated at 4.1%.
The researchers name the largest segment of the market in question as substances used in cardiovascular research. This segment is growing due to improved procedures magnetic resonance imaging in catheterization laboratories, favorable preferential policies related to the diagnosis of cardiovascular diseases, as well as strong infrastructure health care in countries such as the United States, Canada, and. Great Britain Germany
MarketsandMarkets predicts that contrast agents in the form of microbubbles or hollow microbeads will show the largest sales growth between 2016 and 2021, which will be facilitated by academic research exploring new ways to diagnose and deliver medicines.
According to the results of 2015, analysts call the following companies the largest manufacturers of contrast drugs:
- Bayer HealthCare (Germany);
- GE Healthcare (USA);
- Guerbet Group (France);
- Bracco Imaging S.p.A. (Italy).
These manufacturers are leading thanks to their wide presence in more than 50 countries, large investments in research and development, as well as a developed distribution channel. Lantheus Medical Imaging (USA), nanoPET Pharma (Germany), CMC Contrast (Sweden), Daiichi Sankyo (Japan) and Subhra Pharma Private Limited (India) also operate in the contrast media market. Contrast Media/Contrast Agent Market by Type (Iodinated, Gadolinium, Barium, & Microbubble), Procedure (X-Ray/CT, MRI, & Ultrasound) & Application (Radiology, Interventional Radiology, & Interventional Cardiology) - Global Forecasts to 2021[1]
2015: GlobalData: Market Size $4.3 Billion
In April 2016, the analytical company GlobalData published some results of a study of the global contrast substances market. Its volume, according to experts, exceeded $4.3 billion in 2015.
According to the researchers, in the period from 2015 to 2022, sales of contrast agents will grow by an average of 4.9% annually and will amount to more than $6 billion by the end of this period of time. The rise will be observed in all major markets for these substances, such as, USA,, France,, Germany,, Italy,, and Spain. Great Britain Japan Brazil China India
The increase in demand for contrast drugs is facilitated by an increase in the number of examinations using computer and magnetic resonance imaging, as well as using ultrasound cardiography (ultrasound of the heart). In addition, the growing burden of disease is taking a toll, GlobalData said in a report.
As the number of people on the planet increases, the rate of development of diseases also increases, as does the need for diagnostic interventions and the use of contrast media, says GlobalData analyst Mandeep Sanghera.
According to him, another factor in the rise of the contrast agents market is the increase in the efficiency of medical systems and educational programs. For example, the practice of screening patients for diseases such as breast cancer and colorectal cancer is spreading from developed countries to developing countries, Sanghera notes.[2]
See also
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |